Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Ovarian Neoplasms

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 48 articles: HTML format Text format

Single Articles

December 2011
1. KONSTANTINOPOULOS PA , Cannistra SA
   Comparing Poly (ADP-Ribose) Polymerase Inhibitors With Standard Chemotherapy in BRCA-Mutated, Recurrent Ovarian Cancer: Lessons Learned From a Negative Trial.
   J Clin Oncol. 2011.
   PubMed     Text format     Related articles   
   
   
   
   
2. KAYE SB , Lubinski J, Matulonis U, Ang JE, et al
   Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer.
   J Clin Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. SOOD AK , Coleman RL, Ellis LM
   Moving Beyond Anti-Vascular Endothelial Growth Factor Therapy in Ovarian Cancer.
   J Clin Oncol. 2011.
   PubMed     Text format     Related articles   
   
   
   
   
4. KARLAN BY , Oza AM, Richardson GE, Provencher DM, et al
   Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer.
   J Clin Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. LI HK , Harding V, Williamson R, Blagden S, et al
   Cerebral Sinus Thrombosis and Leptomeningeal Carcinomatosis in a Patient With Ovarian Cancer.
   J Clin Oncol. 2011.
   PubMed     Text format     Related articles   
   
   
   
   November 2011
6. HALBERT CH , Stopfer JE, McDonald J, Weathers B, et al
   Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns?
   J Clin Oncol. 2011;29:4302-6.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. KONNER JA , Grabon DM, Gerst SR, Iasonos A, et al
   A Phase II Study of Intraperitoneal Paclitaxel Plus Cisplatin and Intravenous Paclitaxel Plus Bevacizumab As Adjuvant Treatment of Optimal Stage II/III Epithelial Ovarian Cancer.
   J Clin Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. CHI DS , Bristow RE, Armstrong DK, Karlan BY, et al
   Is the easier way ever the better way?
   J Clin Oncol. 2011;29:4073-5.
   PubMed     Text format     Related articles   
   
   
   
   October 2011
9. ROHSBACH D , Trillsch F, Regier M, Choschzick M, et al
   Malignant transformation of a serous borderline tumor and early metastasis of associated low-grade serous carcinoma detected on screening mammography.
   J Clin Oncol. 2011;29:e763-5.
   PubMed     Text format     Related articles   
   
   
   
   September 2011
10. VERGOTE I , Trope CG, Amant F, Ehlen T, et al
    Neoadjuvant Chemotherapy Is the Better Treatment Option in Some Patients With Stage IIIc to IV Ovarian Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
11. VIANA LS , Tsunoda AT, Nunes JS, Fregnani JH, et al
    Preservation of Pregnancy in a Patient With Acute Abdominal Pain Secondary to Advanced and Hemorrhagic Yolk Sac Tumor of the Right Ovary.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
12. FAIRFIELD KM , Murray K, Lucas FL, Wierman HR, et al
    Completion of Adjuvant Chemotherapy and Use of Health Services for Older Women With Epithelial Ovarian Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
13. LEDERMANN JA , Hackshaw A, Kaye S, Jayson G, et al
    Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. PIGNATA S , Scambia G, Ferrandina G, Savarese A, et al
    Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. NORQUIST B , Wurz KA, Pennil CC, Garcia R, et al
    Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
    J Clin Oncol. 2011;29:3008-15.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
16. GUO JJ , Liu W, Yang H, Qian H, et al
    Multiple Osteolytic Bone Lesions 3 Years After Ovarian Cancer: Benign or Malignant?
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
17. KHAN MI , Waguespack SG, Habra MA, Broaddus R, et al
    Acute-onset ectopic adrenocorticotropic hormone syndrome secondary to metastatic endometrioid carcinoma of the ovaries as a fatal complication.
    J Clin Oncol. 2011;29:e462-4.
    PubMed     Text format     Related articles   
    
    
    
    May 2011
18. NAGLE CM , Francis JE, Nelson AE, Zorbas H, et al
    Reducing Time to Diagnosis Does Not Improve Outcomes for Women With Symptomatic Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    March 2011
19. BACH PB , Vickers AJ
    Do the Data Support the Comorbidity Hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Results?
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
20. PANDEY M , Truica C
    Hepatoid Carcinoma of the Ovary.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
21. COHN DE , Kim KH, Resnick KE, O'Malley DM, et al
    At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. HENSLEY ML
    Big Costs for Little Gain in Ovarian Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
23. SHERRIFF JM , Walji N
    Prolonged survival in a patient with multiple metachronous tumors.
    J Clin Oncol. 2011;29:e154-5.
    PubMed     Text format     Related articles   
    
    
    
    January 2011
24. CHRISTOULAS D , Matsouka C, Chatzinikolaou I, Barmparoussi D, et al
    Relapse of Ovarian Cancer With Bone Marrow Infiltration and Concurrent Emergence of Therapy-Related Acute Myeloid Leukemia: A Case Report.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    November 2010
25. SEHOULI J , Stengel D, Harter P, Kurzeder C, et al
    Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. MATEI D , Sill MW, Lankes HA, Degeest K, et al
    Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. SERRANO C , Garcia A, Brana I, Perez-Benavente A, et al
    Angiosarcoma of the ovary: is it always a lethal disease?
    J Clin Oncol. 2010;28:e675-7.
    PubMed     Text format     Related articles   
    
    
    
    
28. KANDALAFT LE , Powell DJ Jr, Singh N, Coukos G, et al
    Immunotherapy for Ovarian Cancer: What's Next?
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
29. VAN DER VORST MJ , Bleeker MC, Boven E
    Unusual presentation of granulosa cell tumor of the ovary.
    J Clin Oncol. 2010;28:e554-6.
    PubMed     Text format     Related articles   
    
    
    
    
30. VEECK J , Ropero S, Setien F, Gonzalez-Suarez E, et al
    BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors.
    J Clin Oncol. 2010;28:e563-4.
    PubMed     Text format     Related articles   
    
    
    
    August 2010
31. DU BOIS A , Herrstedt J, Hardy-Bessard AC, Muller HH, et al
    Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. LOMAN N , Borg A
    Improving surveillance and quality of life of BRCA mutation carriers.
    J Clin Oncol. 2010;28:e376-7.
    PubMed     Text format     Related articles   
    
    
    
    July 2010
33. HENNESSY BT , Timms KM, Carey MS, Gutin A, et al
    Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2010
34. KONSTANTINOPOULOS PA , Spentzos D, Karlan BY, Taniguchi T, et al
    Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. BAST RC JR , Mills GB
    Personalizing Therapy for Ovarian Cancer: BRCAness and Beyond.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
36. MAURIE M
    Serious Ethical Dilemma of Single-Agent Pegylated Liposomal Doxorubicin Employed As a Control Arm in Ovarian Cancer Chemotherapy Trials.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
37. CANNISTRA SA
    Evaluating New Regimens in Recurrent Ovarian Cancer: How Much Evidence Is Good Enough?
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
38. MONK BJ , Herzog TJ, Kaye SB, Krasner CN, et al
    Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2010
39. PUJADE-LAURAINE E , Wagner U, Aavall-Lundqvist E, Gebski V, et al
    Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2010
40. GOURLEY C , Michie CO, Roxburgh P, Yap TA, et al
    Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. FONG PC , Yap TA, Boss DS, Carden CP, et al
    Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. CHOO BA , Walji N, Spooner D, Barber P, et al
    Prolonged Relapse-Free Survival in Two Patients With an Isolated Brain Metastasis From Epithelial Ovarian Carcinoma.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
43. YURKOVETSKY Z , Skates S, Lomakin A, Nolen B, et al
    Development of a Multimarker Assay for Early Detection of Ovarian Cancer.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. HENSLEY ML
    A Step Forward for Two-Step Screening for Ovarian Cancer.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles   
    
    
    
    March 2010
45. SATOH T , Hatae M, Watanabe Y, Yaegashi N, et al
    Outcomes of Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer: A Proposal for Patient Selection.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. DU BOIS A , Reuss A, Harter P, Pujade-Lauraine E, et al
    Potential Role of Lymphadenectomy in Advanced Ovarian Cancer: A Combined Exploratory Analysis of Three Prospectively Randomized Phase III Multicenter Trials.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2010
47. KURIAN AW , Sigal BM, Plevritis SK
    Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.
    J Clin Oncol. 2010;28:222-31.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2009
48. SINGHAL MK , Krishnan V, Singh S, Kumar R, et al
    Isolated Ovarian Relapse in a 68-Year-Old Woman With Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles   
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: